双鹭药业：2025年前三季度净利润约1.41亿元

Company Performance - Double-Helix Pharmaceutical reported a revenue of approximately 459 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 15.13% [1] - The net profit attributable to shareholders of the listed company was approximately 141 million yuan, showing a significant year-on-year increase of 943.1% [1] - Basic earnings per share reached 0.1373 yuan, which is an increase of 942.33% compared to the previous year [1] Market Capitalization - As of the report, the market capitalization of Double-Helix Pharmaceutical stands at 7.7 billion yuan [2]